| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 2 131-135, Copyright © 1992 by American Association for Cancer Research
ARTICLES |
JO Boyle, FL Meyskens Jr, HS Garewal and EW Gerner
University of Arizona, Arizona Cancer Center, Tucson.
Difluoromethylornithine (DFMO) is an investigational chemopreventive agent that inhibits ornithine decarboxylase (ODC) activity, lowers cellular polyamine concentrations, and decreases cell proliferation in vivo and in vitro. In five subjects we have compared the polyamine concentrations in rectal mucosal biopsies and in exfoliated buccal mucosal cells (EBM) before and after DFMO treatment to assess the suitability of EBM as an easily accessible marker tissue for DFMO suppression of polyamine synthesis in the rectal mucosa. One month of 3 g/m2/day of DFMO treatment caused a statistically significant decrease in putrescine and spermidine concentrations in rectal mucosa biopsy specimens but not in EBM samples. ODC activity in EBM was high (approximately 1 mumol/min/mg protein), resistant to DFMO inhibition (Ki = 4200 microM), dependent on GTP concentration (maximal at 0.1 mM), and was reduced concomitantly with bacterial concentration by antiseptic mouthwashing. Bacteria adherent to EBM were visible by electron microscopy. Forty bacterial colonies/ng protein were culturable from washed EBM samples. Oral bacteria preclude the use of EBM samples as a marker tissue of DFMO effect in the rectal mucosa, but oral DFMO therapy is effective in depleting polyamines in rectal mucosa.
This article has been cited by other articles:
|
|
 |
|
  A. R. Simoneau, E. W. Gerner, R. Nagle, A. Ziogas, S. Fujikawa-Brooks, H. Yerushalmi, T. E. Ahlering, R. Lieberman, C. E. McLaren, H. Anton-Culver, et al. The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3 Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Lao, P. Backoff, L. I. Shotland, D. McCarty, T. Eaton, F. G. Ondrey, J. L. Viner, S. J. Spechler, E. T. Hawk, and D. E. Brenner Irreversible Ototoxicity Associated with Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1250 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Armstrong, A. R. Kennedy, X. S. Wan, T. H. Taylor, Q. A. Nguyen, J. Jensen, W. Thompson, W. Lagerberg, and F. L. Meyskens Jr. Clinical Modulation of Oral Leukoplakia and Protease Activity by Bowman-Birk Inhibitor Concentrate in a Phase IIa Chemoprevention Trial Clin. Cancer Res., December 1, 2000; 6(12): 4684 - 4691. [Abstract] [Full Text]
|
|
|
|
|
|
F. L. Meyskens Jr. and E. W. Gerner Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent Clin. Cancer Res., May 1, 1999; 5(5): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
